BITCOIN-CAPITAL
2.12.2021 09:13:12 CET | Business Wire | Press release
Bitcoin Capital announced today that it has again listed two world firsts on the SIX Swiss Exchange. With 1 FiCAS Active Bitcoin ETP and 1 FiCAS Active Ethereum ETP, the company has launched two products actively managed by the highly experienced crypto asset manager FICAS AG . With active management, the products aim to counter negative price fluctuations and therefore outperform the two largest cryptocurrencies by capitalization. With the listing, institutional, professional, and private investors in Switzerland, Liechtenstein, and the European Union (excluding Hungary) can easily invest in the new products via their bank or broker, just as they do with other listed financial investments such as equities or bonds.
"Our purpose is to grant investors safe and easy access to digital assets and are convinced that crypto assets will soon be part of the diversification strategy of many investment portfolios. The two new products with the most relevant cryptocurrencies as underlying may, through their active management, improve the overall portfolio risk by reducing underlying volatility," said Dr. Luca Schenk, Chairman of Bitcoin Capital AG .
As a pioneer in innovative investment products, Bitcoin Capital AG has already proven itself in 2020 with the launch of the world's first exchange-listed actively managed crypto ETP - 15 FiCAS Active Crypto ETP (Symbol BTCA | ISIN CH0548689600). With the new products, the crypto journey will be far from over and more investment solutions are already being planned.
About Bitcoin Capital AG
Bitcoin Capital AG is a subsidiary of FiCAS AG. The company issued the world's first actively managed and listed crypto ETP which was listed on the Swiss stock exchange in 2020. Bitcoin Capital offers asset managers the possibility to white-label and launch actively managed exchange-listed products.
About FiCAS AG
FiCAS AG is a Swiss-based crypto investment management boutique. The firm manages FiCAS Active Crypto ETP - the world's first actively managed exchange-traded product (ETP) with cryptocurrencies as underlying assets, issued by Bitcoin Capital AG. FiCAS AG's discretionary investment strategy is based on fundamental and technical analysis, proprietary algorithms, and quant signals from experienced analysts. The founder of FiCAS AG, Ali Mizani Oskui, has a proven track record of outperforming crypto market trends. The portfolio he managed from October 2015 to January 2018 outperformed bitcoin holding strategy returns by 110% over the same period, as audited by a "Big Four" advisory firm. FiCAS AG was founded in 2019 and is led by a team of professionals with deep knowledge of both crypto finance and traditional finance.
Disclaimer
This communication does not qualify as investment advice nor constitutes an offer of securities for sale. No liability shall be accepted for the accuracy and completeness of the information contained in this communication. Past performance, returns generated through FiCAS AG's and its founder's management strategy, and correct price predictions by FiCAS AG' founder are not necessarily indicative of future results. The information contained herein is not for release, publication, or distribution, in whole or in part, directly or indirectly, in or into Australia, Canada, Japan, Hong Kong, New Zealand, Singapore, South Africa, United Kingdom, United States, or such other countries or otherwise in such circumstances in which the release, publication or distribution would be unlawful. Any securities pursuant to this communication have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or under the applicable securities laws of any state of the United States and may not be offered or sold, directly or indirectly, within the United States or to, or for the account or benefit of, U.S. persons except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. The investment products described in this communication are intended for retail, professional and institutional investors in Switzerland, Liechtenstein, and in the European Union (excl. Hungary).
www.bitcoincapital.com | www.ficas.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20211202005363/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom